We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Cell Viability Tests Compared with Microchip Method

By LabMedica International staff writers
Posted on 12 Apr 2011
A technique for the automatic cell viability measurement with a microscopic cell counter and microchip has been evaluated.

An appraisal has been made of different methods of cell viability testing, an essential tool for performing cell-based studies and clinical laboratory tests.

Scientists at Korea University Guro Hospital (Seoul, Korea) compared three different methods to test the viability of blood cells. Blood was drawn from 11 healthy volunteers and mononuclear cells were separated immediately from the heparinized whole blood, and the viable cells were diluted subsequently down from 100% to, 75%, 50%, 25%, and 1%. The cell viability tests were performed simultaneously with the following three methods: the conventional manual trypan blue exclusion method; the flow cytometry measurement with propidium iodide stain; and the newly developed automated fluorescence microscopic cell counter with microchip.

The linearity, precision, and correlations from three methods were analyzed and compared. The correlations data from the microscopic cell counter were in good agreement with both the conventional trypan blue method and the flow cytometry. The precision and linearity from the microscopic cell counter method with microchip were superior in comparison with the conventional method. The new microscopic cell counter with microchip, known as Adam (NanoenTek, Inc.; Seoul, Korea), was further developed and improved to produce the results within five minutes, including all procedural steps.

In the manual trypan blue stain, only 200 cells were counted to measure their viability, but in Adam, larger number of cells, approximately between 1,000 and 3,000 cells, were counted. Greater number of counted cells and the repetitions of the experiments by the microscopic cell counter and microchip for the analyses provided the better statistical significance. The real-time cellular images and archived data could also be used for analyzing other parameters. The study was published online on March 15, 2011, in the Journal of Clinical Laboratory Analysis.

Related Links:
Korea University Guro Hospital
NanoenTek, Inc.


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ESR Analyzer
miniiSED™

Latest Immunology News

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
12 Apr 2011  |   Immunology

Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
12 Apr 2011  |   Immunology

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions
12 Apr 2011  |   Immunology